Equal-WT
WhaleScore 2.0
?
Affinity Asset Advisors is based out of New York. Affinity Asset Advisors is a hedge fund with 2 clients and discretionary assets under management (AUM) of $553,053,373 (Form ADV from 2024-03-28). Their last reported 13F filing for Q3 2024 included $732,761,256 in managed 13F securities
and a top 10 holdings concentration of 42.15%. Affinity Asset Advisors's largest holding is Xenon Pharmaceuticals Inc with shares held of 1,144,021. Whalewisdom has at least 17 13F filings, and 13 13G filings
Business Description
Affinity Asset Advisors, LLC, a Delaware limited liability company formed in 2017, is an investment advisor to private fund clients. The firm was founded by Michael Cho and Jonathan Chu, with Mr. Cho serving as the Portfolio Manager and Mr. Chu as the Chief Compliance Officer. Affinity's principal place of business is in New York, New York.
Affinity provides investment advisory services on a discretionary basis to private fund clients, including the Affinity Healthcare Fund, LP. The firm relies heavily on the services of its Portfolio Manager for all investment decisions, and investors have no right to participate in these decisions. As a result, the success of the clients depends largely on the abilities of key personnel, and any termination, death, or incapacitation of these individuals could negatively impact the profitability of the clients.
Investment Strategy
The Funds, through their investments in the Master Fund, pursue an active long-short equity strategy focused on the healthcare sector. Generally, healthcare investments will focus on pharmaceutical and biotechnology companies that develop, discover, and commercialize drug therapies.
The Funds, through the Master Fund, also invest opportunistically across the capital structure, including investments in credit instruments, private transactions, and alternative investments, which may include but are not limited to special purpose acquisition companies.
Owners
- HELLER, DANIEL, BARRY - CHIEF INVESTMENT OFFICER | MEMBER
- CHO, MICHAEL - CO-FOUNDER, MANAGING PARTNER AND PORTFOLIO MANAGER | MANAGING MEMBER
- CHU, JONATHAN, BO-SHING - CO-FOUNDER AND CHIEF COMPLIANCE OFFICER | MEMBER
- NOSKER, PATRICK, LEONARD - DIRECTOR OF RESEARCH | MEMBER Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)

2024-09-30
Top Buys (13F)
Name | % Change |
---|---|
SAVA Cassava Sciences Inc (PUT) | 5.82% |
NUVL Nuvalent Inc | 2.96% |
ALKS Alkermes Plc | 2.01% |
XENE Xenon Pharmaceutical | 1.68% |
VRDN Viridian Therapeutic | 1.4% |

2024-09-30
Top Sells (13F)
Name | % Change |
---|---|
SPY SPDR S&P 500 ETF TRU (PUT) | 21.96% |
CERE Cerevel Therapeutics | 2.36% |
DEBT-BRID BRIDGEBIO PHARMA INC (PRN) | 1.99% |
DEBT-ALNY ALNYLAM PHARMACEUTIC (PRN) | 1.87% |
CLDX Celldex Therapeutics | 1.45% |

2024-09-30
13F Holdings Summary
Name | $ Change |
---|---|
XENE Xenon Pharmaceutical | 6.15% |
SAVA Cassava Sciences Inc(PUT) | 5.82% |
APGE Apogee Therapeutics | 5.32% |
NUVL Nuvalent Inc | 4.71% |
ACLX Arcellx Inc | 4.56% |

2024-09-30
13F Activity
Market Value | $0.73b, Prior: $0.87b |
Inflows (Outflows) as % of Total MV | (-22.9062)% |
New Purchases | 16 stocks |
Added To | 26 stocks |
Sold out of | 28 stocks |
Reduced holdings in | 29 stocks |
Top 10 Holdings % | 42.15% |
Turnover %[1] | 38.6% |
Turnover Alt %[2] | 24.78% |
Time Held Top 20 | 2.55 quarters |
Time Held Top 10 | 2.2 quarters |
Time Held All | 3.73 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.

2024-09-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data

2024-09-30
Analysis

Top 20 equal-weighted holdings. Performance numbers calculated through 2024-09-30